D-0700-2017 Class III Terminated

Recalled by Sun Pharmaceutical Industries, Inc. — Cranbury, NJ

FDA drug recall D-0700-2017 was initiated by Sun Pharmaceutical Industries, Inc. on Mar 22, 2017 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities). The recall status is terminated (terminated Jul 11, 2018). Affected quantity: 6,138 bottles.

Recall details

Product Type
Drugs
Report Date
May 17, 2017
Initiation Date
Mar 22, 2017
Termination Date
Jul 11, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6,138 bottles

Product description

Olanzapine Tablets, 7.5 mg, packaged in a) 30-count bottles (NDC 62756-553-83), b) 100-count bottles (NDC 62756-553-88), and c) 1000-count bottles (NDC 62756-553-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.

Reason for recall

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot #: a) JKP3150B, Exp 06/17, JKR5749A, Exp 06/18; b) JKP2757A, Exp 05/17, JKP3149A, JKP3150A, Exp 06/17, JKR5049A, Exp 04/18; c) JKP2758B, Exp 05/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0700-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0700-2017. Report a data issue: hello@regdatalab.com.